[1] Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for de-mentia associated with Parkinson's disease[J]. Movement Disorders, 2007, 22(12):1689-1707.
[2] Litvan I, Goldman J G, Tröster A I, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease:Movement disorder society task force guidelines[J]. Movement Disorders, 2012, 27(3):349-356.
[3] Copeland J N, Lieberman A, Oravivattanakul S, et al. Accuracy of pa-tient and care partner identification of cognitive impairments in Parkin-son's disease-mild cognitive impairment[J]. Movement Disorders, 2016, 31(5):693-698.
[4] Williams-Gray C H, Mason S L, Evans J R, et al. The campaign study of Parkinson's disease:10-year outlook in an incident populationbased cohort[J]. Journal of Neurology, Neurosurgery, and Psychiatry, 2013, 84(11):1258-1264.
[5] Hely M A, Reid W G, Adena M A, et al. The sydney multicenter study of Parkinson's disease:The inevitability of dementia at 20 years[J]. Movement Disorders, 2008, 23(6):837-844.
[6] Pigott K, Rick J, Xie S X, et al. Longitudinal study of normal cognition in Parkinson disease[J]. Neurology, 2015, 85(15):1276-1282.
[7] Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update:Treatments for the non-motor symptoms of Parkinson's disease[J]. Movement Disorders, 2011, 26(Sup-pl 3):S42-80.
[8] Goldman J G, Weintraub D. Advances in the treatment of cognitive im-pairment in Parkinson's disease[J]. Movement Disorders, 2015, 30(11):1471-1489.
[9] Parsons T D, Rogers S A, Braaten A J, et al. Cognitive sequelae of sub-thalamic nucleus deep brain stimulation in Parkinson's disease:A me-ta-analysis[J]. Lancet Neurology, 2006, 5(7):578-588.
[10] Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease:A ran-domised, multicentre study[J]. Lancet Neurology, 2008, 7(7):605-614.
[11] Alomar S, King N K, Tam J, et al. Speech and language adverse ef-fects after thalamotomy and deep brain stimulation in patients with movement disorders:A meta-analysis[J]. Movement Disorders, 2017, 32(1):53-63.
[12] Daniels C, Krack P, Volkmann J, et al. Risk factors for executive dys-function after subthalamic nucleus stimulation in Parkinson's disease[J]. Movement Disorders, 2010, 25(11):1583-1589.
[13] Leung I H, Walton C C, Hallock H, et al. Cognitive training in Parkin-son disease:A systematic review and meta-analysis[J]. Neurology, 2015, 85(21):1843-1851.
[14] Costa A, Peppe A, Dell'Agnello G, et al. Dopamine and cognitive func-tioning in de novo subjects with Parkinson's disease:Effects of prami-pexole and pergolide on working memory[J]. Neuropsychologia, 2009, 47(5):1374-1381.
[15] Durstewitz D and Seamans J K The dual-state theory of prefrontal cor-tex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia[J]. Biological Psychiatry, 2008, 64(9):739-749.
[16] Ye Z, Altena E, Nombela C, et al. Selective serotonin reuptake inhibi-tion modulates response inhibition in Parkinson's disease[J]. Brain, 2014, 137(4):1145-55.
[17] Ye Z, Altena E, Nombela C, et al. Improving response inhibition in Parkinson's disease with atomoxetine.[J]. Biological Psychiatry, 2015, 77(8):740-748.
[18] Healy D G, Falchi M, O'Sullivan S S, et al. Phenotype, genotype, and worldwide genetic penetrance of lrrk2-associated Parkinson's disease:A case-control study[J]. Lancet Neurology, 2008, 7(7):583-590.
[19] Wang C, Cai Y, Gu Z, et al. Clinical profiles of Parkinson's disease as-sociated with common leucine-rich repeat kinase 2 and glucocerebro-sidase genetic variants in Chinese individuals[J]. Neurobiology of Ag-ing, 2014, 35(3):725-726.
[20] Thaler A, Mirelman A, Gurevich T, et al. Lower cognitive performance in healthy g2019s lrrk2 mutation carriers[J]. Neurology, 2012, 79(10):1027-1032.
[21] Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease[J]. Brain, 2009, 132(7):1783-1794.
[22] Winder-Rhodes S E, Evans J R, Ban M, et al. Glucocerebrosidase mu-tations influence the natural history of Parkinson's disease in a com-munity-based incident cohort[J]. Brain, 2013, 136(2):392-399.
[23] Zhang Y, Sun Q Y, Zhao Y W, et al. Effect of gba mutations on pheno-type of Parkinson's disease:A study on Chinese population and a me-ta-analysis[J]. Parkinson's Disease, 2015, 2015:916971.
[24] Mata I F, Leverenz J B, Weintraub D, et al. Gba variants are associat-ed with a distinct pattern of cognitive deficits in Parkinson's disease[J]. Movement Disorders, 2016, 31(1):95-102.
[25] Cilia R, Tunesi S, Marotta G, et al. Survival and dementia in gba-asso-ciated Parkinson's disease:The mutation matters[J]. Annals of Neurol-ogy, 2016, 80(5):662-673.
[26] Williams-Gray C H, Evans J R, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease:5 year follow-up of the campaign cohort[J]. Brain, 2009, 132(Pt11):2958-2969.
[27] Nombela C, Rowe J B, Winder-Rhodes S E, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease:Icicle-pd study[J]. Brain, 2014, 137(10):2743-2758.
[28] Mata I F, Leverenz J B, Weintraub D, et al. Apoe, mapt, and snca genes and cognitive performance in Parkinson disease[J]. JAMA Neu-rology, 2014, 71(11):1405-1412.
[29] Federoff M, Jimenez-Rolando B, Nalls M A, et al. A large study re-veals no association between apoe and Parkinson's disease[J]. Neurobi-ology of Disease, 2012, 46(2):389-92.
[30] Kurz M W, Dekomien G, Nilsen O B, et al. Apoe alleles in Parkinson disease and their relationship to cognitive decline:A populationbased, longitudinal study[J]. Journal of Geriatric Psychiatry and Neu-rology, 2009, 22(3):166-170.
[31] Pushpanathan M E, Loftus A M, Thomas M G, et al. The relationship between sleep and cognition in Parkinson's disease:A meta-analysis[J]. Sleep Medicine Reviews, 2016, 26:21-32.
[32] Anang J B, Gagnon J F, Bertrand J A, et al. Predictors of dementia in Parkinson disease:A prospective cohort study.[J]. Neurology, 2014, 83(14):1253-1260.
[33] Domellöf M E, Lundin K F, Edström M, et al. Olfactory dysfunction and dementia in newly diagnosed patients with Parkinson's disease[J]. Parkinsonism & Related Disorders, 2017, Epub ahead of print.
[34] Morley J F, Weintraub D, Mamikonyan E, et al. Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's dis-ease[J]. Movement Disorders, 2011, 26(11):2051-2057.
[35] den Brok M G, van Dalen J W, van Gool W A, et al. Apathy in Par-kinson's disease:A systematic review and meta-analysis[J]. Move-ment Disorders, 2015, 30(6):759-769.
[36] Allcock L M, Kenny R A, Mosimann U P, et al. Orthostatic hypoten-sion in Parkinson's disease:Association with cognitive decline[J]. In-ternational Journal of Geriatric Psychiatry, 2006, 21(8):778-783.
[37] Hohler A D, Zuzuárregui J R, Katz D I, et al. Differences in motor and cognitive function in patients with Parkinson's disease with and without orthostatic hypotension[J]. International Journal of Neurosci-ence, 2012, 122(5):233-236.
[38] Idiaquez J, Benarroch E E, Rosales H, et al. Autonomic and cognitive dysfunction in Parkinson's disease[J]. Clinical Autonomic Research, 2007, 17(2):93-98.
[39] Peralta C, Stampfer-Kountchev M, Karner E, et al. Orthostatic hypo-tension and attention in Parkinson's disease with and without dementia[J]. Journal of Neural Transmission (Vienna), 2007, 114(5):585-588.
[40] Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, et al. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease[J].Movement Disorders, 2016, 31(6):861-881.
[41] Leaver K and Poston K L Do csf biomarkers predict progression to cog-nitive impairment in Parkinson's disease patients? A systematic review[J]. Neuropsychological Review, 2015, 25(4):411-423.
[42] Schrag A, Siddiqui U F, Anastasiou Z, et al. Clinical variables and biomarkers in prediction of cognitive impairment in patients with new-ly diagnosed Parkinson's disease:A cohort study[J]. Lancet Neurology, 2017, 16(1):66-75.
[43] Ye Z, Rae C L, Nombela C, et al. Predicting beneficial effects of atom-oxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.[J]. Human Brain Mapping, 2016, 37(3):1026-1037.
